Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study.

A claims-based analysis quantified the clinical and economic burden of myotonic dystrophy type 1 (DM1) on the U.S. healthcare system, finding that affected patients experience substantially higher rates of comorbidities and healthcare utilization compared to unaffected individuals. DM1 is a multisystem neuromuscular disease with relevance to physical therapy given its impact on muscle function, mobility, and respiratory health. The study highlights the significant resource demands placed on the healthcare system by this population.

Read full article at PubMed / J Med Econ ↗

About this summary. The text above is a short summary written for this site. The original article is hosted by PubMed / J Med Econ at the link above; this site does not reproduce the full article. Verify against the source before relying on specific details.